The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction.
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?
A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review.
Eicosapentaenoic acid inhibits oxidation of very large density lipoproteins (VLDL) in a dose-dependent manner over time as compared to docosahexaenoic acid in vitro [abstract].
Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin
Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid
Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same
Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits
Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes.
Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients
Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements
Omega-3 fatty acid formulations in cardiovascular disease: dietary supplements are not substitutes for prescription products
Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents